Vulvar Cancer
Conditions
Keywords
Vulva
Brief summary
The purpose of this study is to determine if regular and daily repeated application of the ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.
Interventions
DRUGCiclopirox
Sponsors
University of Medicine and Dentistry of New Jersey
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Inclusion criteria
* Patients between the ages 18 and 75 years. * Patients may be carriers of the Human Immunodeficiency Virus (HIV). * Patients must have been diagnosed with precancerous lesion(s) of the vulva by tissue sampling (biopsy-proven vulvar intraepithelial neoplasia grade II or III) * Patients must be able to come to University Hospital for their initial appointment in Gynecologic Oncology Clinic, and for the eight follow-up visits in that Clinic required by the protocol.
Exclusion criteria
* Pregnant or patients who are breast feeding a baby. * Patients who have been diagnosed with a vaginal yeast infection. * Patients who have undergone prior surgery for precancerous lesion(s) of the vulva.
Countries
United States
Outcome results
None listed